Courthouse News reports:
An independent advisory panel for the U.S. Centers for Disease Control and Prevention voted Friday to recommend the continued use of the Johnson & Johnson Covid-19 vaccine after the single-dose jab was put on pause over blood clotting concerns.
Friday’s vote followed similar concerns in the Europe Union over both the J&J jab and the AstraZeneca vaccine, which also faced concerns over blood clots.
Like AstraZeneca, the European Medicines Agency found a link between the J&J vaccine and very rare cases of blood clots, but said its benefits far outweigh the risks. EU member states began administering the shot this week.
Read the full article.
JUST IN: A CDC advisory panel recommends the U.S. resume using the J&J Covid vaccine, saying the benefits outweigh the risk. @megtirrell reports. https://t.co/tpFvuGgaVV pic.twitter.com/YVAN1yoeRw
— CNBC (@CNBC) April 23, 2021